One Health vision: human, animal, and environmental health

Technology in the service of health

State-of-the-art solutions

Innovation and sustainability

Category: Previous news

  • OSASUNBERRI, a collaborative initiative for innovation and investment in the Km 0 health industry and in a cutting-edge healthcare system.

    OSASUNBERRI, a collaborative initiative for innovation and investment in the Km 0 health industry and in a cutting-edge healthcare system.

    OSASUNBERRI, an inter-regional collaborative initiative for innovation and investment in the Km 0 health industry and in the health care system, was presented in Bilbao on 4 October. Its aim is to join forces, create synergies and strengthen this sector in order to achieve efficient, comprehensive and sustainable management of current needs, as well as those arising from emerging risks in the field of health, such as the one experienced by COVID-19.

    The 27 organisations participating in the initiative were present at the event, accompanied by the Basque Government’s Regional Minister for Economic Development, Sustainability and the Environment, Arantxa Tapia, and the Regional Minister for Economic and Business Development of the Government of Navarre, Mikel Irujo.

    The objectives of OSASUNBERRI focus on four aspects: the industrial tractor effect, sectoral integration of the value chain, inter-regionality, and taking advantage of synergies in knowledge and professional experience.

    A total of 25 companies from the Basque Country and Navarre, together with the Basque Health Cluster and ASEBIO, are collaborating in this project to achieve viable, competitive and efficient solutions for situations of maximum social interest, such as the current pandemic, but fundamentally, to achieve a health industry and a strengthened and competitive healthcare system.

    OSASUNBERRI encompasses four areas of action, to develop integral solutions from diagnosis to therapies and innovation and investment in the field of healthcare, all supported by transversal actions in sustainability, digitalisation, knowledge protection, etc.

    With a direct budget of 142 million euros and an induced investment of up to 400 million euros, the project is aligned with the strategic objectives of the Next Generation funds, generating jobs and investment in infrastructure and research, and fostering entrepreneurship and regional development.

    www.osasunberri.com

    https://www.youtube.com/watch?v=mGmlfm6Q-F0

  • New COVID-19 analysis service opens in the Bizkaia Science and Technology Park

    New COVID-19 analysis service opens in the Bizkaia Science and Technology Park

    Obtaining the COVID-19 passport is closer and easier than ever, within reach of companies, organisations and individuals.

    A new extraction point to offer COVID-19 analytical services has opened its doors today 19th July in Building 101 of the Bizkaia Science and Technology Park, thanks to DNA Data and BIOLAN Health.

    A wide range of tests will be offered both to detect SARS-CoV2 infection and to check a possible immunity obtained naturally or generated by vaccination. The tests range from PCR tests and antibody studies by ELISA to rapid antigen and antibody tests, according to your needs, always in a safe and fast way.

    The analytical results will be provided according to each need, ranging from a diagnostic test to the possibility of obtaining the COVID-19 Digital Passport (in force since 1 July), which allows citizens to move freely throughout Europe.

    All you need to do is to go to DNA Data website, go to Covid-19 Tests and book your appointment online. The timetable for sample collection in Zamudio will be from 9 am to 12 noon, Monday to Friday.

    This service arises from the collaboration between the Biotechnological Company BIOLAN Health from Zamudio and the Biomedical Company DNA Data located in the Technological Park of Miramón. Both companies have been part of the BIOLAN Group since 16 July, the day on which BIOLAN became a shareholder of the company from Gipuzkoa.

    This new extraction point in Zamudio is added to the one that DNA Data already has in Miramón, thus completing a highly demanded service in both Technology Parks, mainly aimed at companies and individuals who carry out their activity in the Historical Territories of Gipuzkoa and Bizkaia, as well as anyone who needs it, to help manage the current pandemic in the most effective way possible.

    \"\"

  • The biomedical company DNA Data joins the BIOLAN Group allowing an ambitious expansion of the portfolio of products and services within the business group.

    The biomedical company DNA Data joins the BIOLAN Group allowing an ambitious expansion of the portfolio of products and services within the business group.

    This operation between both companies strengthens its technological offer and its positioning in the health and food market.

    The first action derived will be the opening, next July 19th, of a COVID-19 analysis service in Zamudio, in the Science and Technology Park of Bizkaia.

    This week has been signed the entry of the Zamudio biotech company BIOLAN Microbiosensores in the capital of the biomedical company DNA Data located in the Miramón Technology Park, representing another example of consolidation of the BIOLAN Group, both in the food and health fields.

    DNA Data is a biomedical company specialised in genetic and biological studies for the diagnosis of diseases of genetic origin. Its field of action is oriented towards any medical discipline, applying research, development and application of new technologies in the field of biomedicine. This clinical orientation allows DNA Data to carry out genetic studies always oriented to the diagnosis and prevention of pathologies, with a high specialisation that allows it to have among its network of clients large hospitals of the public network at national level.

    BIOLAN is a world leader in biosensorics applied to the food sector, which has also led it to extend its technology to the world of health, through its BIOLAN Health division. BIOLAN develops, manufactures and markets its own products, the result of its innate commitment to R&D and continuous innovation, which has allowed it to place its innovative offer in more than 60 countries, and therefore, a significant sustained business growth in recent years.

    The investment operation between these Basque companies responds to the common strategy of establishing synergies, so that they can share knowledge, experience, capabilities and markets. The molecular technologies in which DNA Data has extensive experience will reinforce those already mastered by BIOLAN, such as electrochemistry, biotechnology, lateral flow, electronics, connectivity and Big Data.

    As a result, the technological offer of innovative products and services will be clearly reinforced and will open new doors for both companies. The first example of collaboration, and in response to the current pandemic context, has materialised with the opening of an extraction point for analytical services. elated to the diagnosis of COVID-19 in Building 101 of the Bizkaia Science and Technology Park in Zamudio. It will offer a wide range of analytical tests to detect both an infection caused by SARS-CoV2 and a possible immunity obtained naturally or generated by vaccination. From PCR or ELISA tests to rapid antigen and antibody tests, depending on your needs and always in a safe and fast way.

    This service is added to the one that DNA Data has already implemented in the Technological Park of Gipuzkoa (Miramón), which helps to manage the pandemic and provides companies and society in general, access to key information to prevent the spread of the virus, as well as the needs or requirements generated by the pandemic to travel or carry out occasional transfers.

    In addition, this service, which will be offered in both technological parks (Bizkaia and Gipuzkoa), will make it possible to obtain the COVID-19 passport, which since 1 July has enabled citizens to move freely around Europe.

    \"\"

  • PREMIO EMPRESA Y SOCIEDAD – José Ignacio Arrieta 2021 granted to BIOLAN by Estrategia Empresarial in collaboration with BBK and Petronor.

    PREMIO EMPRESA Y SOCIEDAD – José Ignacio Arrieta 2021 granted to BIOLAN by Estrategia Empresarial in collaboration with BBK and Petronor.

    Yesterday, June 30, BIOLAN received the EMPRESA Y SOCIEDAD – José Ignacio Arrieta award in its 2021 edition, an award that recognizes the systematic implementation of corporate social responsibility actions and the integration of the SDGs (Sustainable Development Goals) in the corporate strategy.

    This award is granted by Estrategia Empresarial in collaboration with the BBK and Petronor in tribute to José Ignacio Arrieta, who was the founder of Estrategia Empresarial, and admirable example of social responsibility, and who contributed so much to the Basque Country in social and economic matters.

    This award is an important recognition of our way of \”doing business\” and encourages us even more to continue on the path of naturally implementing actions within the framework of the SDGs and integrating them into our corporate strategy. These actions include collaboration with universities and training centers to integrate promising young people into the world of work, social integration, equal opportunities between genders, solidarity in emerging countries and the continuous improvement of our products and processes, with a focus on sustainability and respect for the environment.

    \"\"

  • GALBAIAN presents the GALBAHE Award, inventor of the year 2021, to Arrate Jaureguibeitia, Innovation Director of BIOLAN, at the celebration of the “World IP Day”.

    GALBAIAN presents the GALBAHE Award, inventor of the year 2021, to Arrate Jaureguibeitia, Innovation Director of BIOLAN, at the celebration of the “World IP Day”.

    Arrate Jaureguibeitia, BIOLAN’s Innovation Director, has received the Galbahe award for inventor of the year 2021, not only for the inventions made, also for her ability to manage the protection of intellectual and industrial property in such a way that they bring added value and competitiveness to BIOLAN’s activity.

    Galbahe 2021 is an award granted by the industrial property agency Galbaian, part of the Mondragon Corporation group of companies. The award was presented as part of the ‘World IP Day’, the World Intellectual Property Day, in an event whose theme this year was ‘IP and SMEs: so that ideas reach the market’.

    This award is a recognition of BIOLAN’s efforts to integrate IP into BIOLAN’s innovation strategy. Arrate Jaureguibeitia stands out for her contributions in conceiving improved and innovative solutions that do not infringe IP rights of third parties and for the quality of the patent families in which she has participated as an inventor, as well as for her vision of combining IP strategy and business opportunity when making decisions in this field.

  • BIOLAN and CIC bioGUNE will jointly develop an ELISA test.

    BIOLAN and CIC bioGUNE will jointly develop an ELISA test.

    This collaborative action is part of a broader agreement reached between CIC bioGUNE and BIOLAN in areas aimed at disease diagnosis and other health applications.

    CIC bioGUNE -a member of the Basque Research & Technology Alliance, BRTA- and BIOLAN have signed a collaboration agreement to exchange the knowledge necessary for the development, manufacture and commercialisation of a serological test in ELISA format (immunoassay techniques) to determine the presence of antibodies (IgG and IgM independently against SARS-CoV-2) and its emerging variants.

    CIC bioGUNE will be responsible for the transfer of its own knowledge and technical assistance in the design and performance of immunoassays (ELISA), including screening and selection of the best commercial materials (such as ELISA plates, stabilisers, antibodies, etc.) for this purpose. The CIC bioGUNE team will also participate in the optimisation of immunoassays, according to the need for industrialisation, as well as in the design and execution of pilot studies and validation of serological test prototypes in ELISA format.

    BIOLAN, through the BIOLAN HEALTH division, will be responsible for the industrial scale-up of the serological test in ELISA format for the detection of antibodies against SARS-CoV-2 and its variants. BIOLAN HEALTH will be responsible for ensuring and establishing the regulatory, commercial and exploitation actions for commercial use of the results of the project. The resulting product will reinforce BIOLAN’s contribution of solutions for the control of the pandemic derived from COVID-19, as the company has been commercialising a rapid serological test for the detection of neutralising antibodies against SARS-CoV-2 since January.

    The agreement was signed by Jesús Jiménez, scientific director of CIC bioGUNE, and Larraitz Añorga, general manager of BIOLAN HEALTH. This collaboration is part of a broader agreement reached between CIC bioGUNE and BIOLAN, both located in the Bizkaia Technology Park, in areas aimed at the diagnosis of diseases and other health applications that require the analysis of proteins and compounds for use in medicine.

  • Important collaboration agreement signed between BIOLAN and Morocco’s AGADIR HALIOPÔLE CLUSTER, composed of the public and private sector of the country’s fisheries sector, which will strengthen quality control and food safety.

    Important collaboration agreement signed between BIOLAN and Morocco’s AGADIR HALIOPÔLE CLUSTER, composed of the public and private sector of the country’s fisheries sector, which will strengthen quality control and food safety.

    The recently signed collaboration agreement with Agadir Haliopôle Cluster (AHP) has as its main objective to support the creation of the HALIOLAB laboratory that will use BIOLAN’s BIOFISH technology to ensure adequate quality control of fish products exported from the port of Agadir to Europe and other international markets.

    The AHP cluster was created with the aim of supporting the competitive development of companies operating in the Moroccan fisheries sector, and in this sense, through the signed agreement, BIOLAN becomes a strategic supplier of technology in the field of diagnostics, to help companies exporting fishery products to comply with national and international regulatory requirements in terms of food control and safety, and therefore facilitate the export of their products.

    In addition , during the recent visit to Morocco of BIOLAN’s CEO, Asier Albizu, another agreement was signed with BIOLAN’s scientific collaborator in the country, Dr. Abderrazzak Rachidi, with the aim of accrediting BIOFISH technology before the SEMAC under the 17025 standard, for the measurement of histamine and sulphite. This accreditation will mean a breakthrough for BIOFISH technology to become an official method in Morocco for the determination of these parameters of special relevance for the Moroccan fishing sector.

    Both collaborations recently established by BIOLAN in Morocco will consolidate the currently important presence of BIOLAN in the country, where its technology has a wide recognition, based on a large number of very satisfied customer companies with this solution.

    \"\"

  • BIOLAN launches its rapid serological test for the detection of antibodies against COVID-19 with a guaranteed industrial production capacity.

    BIOLAN launches its rapid serological test for the detection of antibodies against COVID-19 with a guaranteed industrial production capacity.

    The Basque SME located in Zamudio has invested heavily to equip itself with the equipment that will allow it to scale up the new product developed.

    Since January, BIOLAN has a new product developed and validated with excellent results in terms of sensitivity (96%) and specificity (93%) and with all the necessary requirements for its commercialization, such as the CE marking certification, the manufacturing and export licence of the Spanish Agency for Medicines and Medical Devices (AEMPS).

    The serological test COVID-19 IgG/IgM Rapid Test Cassette, developed by BIOLAN HEALTH, allows the detection of antibodies against SARS-CoV-2 in people who are or have been infected by the virus that causes COVID-19 in less than ten minutes and at low cost.

    The differentiating element of this new test is that it can detect antibodies that have the potential to be neutralizing against SARS-CoV-2 because they are directed against the RBD (Receptor Binding Domain) of the spicular (S) protein of the virus, which is responsible for its entry into the cell.

    In this sense, the vaccines that are currently administered, precisely, contain the mRNA of this spicular protein, since the aim of these vaccines is that the patient’s immune system generates this type of neutralizing antibodies. This type of test is useful for identifying people who have antibodies to SARS-CoV-2 and are \”potentially\” immune, for carrying out epidemiological studies to better understand the incidence and spread of the virus, and can also be a useful tool for evaluating the effectiveness of vaccines.

    BIOLAN has decided to commit to the large-scale manufacture of this product line based on lateral flow technology, for which it has set up a new production facility with industrial equipment with the capacity to manufacture 30,000 tests per day, with the support of the Basque Government, through SPRI. Its own production capacity will allow BIOLAN to ensure the commercialization of the test, which is beginning to generate interest among potential distributors such as pharmaceutical companies and also in international markets such as Chile, Ecuador and Morocco, among others, where the processing of authorized import licenses has begun.

    With this commitment, BIOLAN is making its particular contribution in terms of knowledge and infrastructures to help in the management of the pandemic derived from COVID-19 and in the economic reactivation of the country.

  • Biolan successfully positions BIOFISH 300 SULPHITE and BIOMILK 300 lactose for recognition as official methods by the international AOAC.

    Biolan successfully positions BIOFISH 300 SULPHITE and BIOMILK 300 lactose for recognition as official methods by the international AOAC.

    BIOLAN’s BIOFISH 300 SULPHITE biosensor has recently been adopted as First Action Official MethodsSM by the AOAC INTERNATIONAL Panel of Experts for methods of analysis of sulphite in crustaceans, which means that international recognition as an Official Method is now closer.

    This achievement joins the one already achieved in June 2020 by BIOLAN’s BIOMILK 300 LACTOSE, which also obtained the same qualification as First Action Official MethodsSM for the quantification of residual lactose in lactose-free products.

    Being considered as OMA official methods by AOAC INTERNATIONAL will demonstrate that both BIOLAN biosensors guarantee accuracy and reliability comparable to current official reference methods. This recognition will bring a huge competitive value of BIOLAN products in the market, helping the expansion in the different sectors.

    \"\"